Analysis Of The Clinical Effect Of Indomethacin Combined Somatostatin On Preventing Post-ERCP Pancreatitis And Hyperamylasemia

Objective:To investigate the clinical effect of indomethacin combined somatostatin on preventing post-ERCP pancreatitis and hyperamylasemia.Methods:We retrospectively analyze the clinical data of 129 choledocholithiasis cases who were treated by ERCP in the department of hepatobiliary surgery of Chongqing Fuling Central Hospital from March 2014 to December 2015.Among the 129 cases, 66 cases used somatostatin,while 63 cases used indomethacin with somatostatin(hereinafter referred to as somatostatin group and combination group). We compare the differences in the two groups.Results: 1.The incidence of PEP in combination group(3.17%) was lower than that in somatostatin group(13.64%)(P<0.05). 2.The incidence of hyperamylasemia in combination group(12.69%) was lower than that in somatostatin group(22.73%), but the difference was not statistically significant(P > 0.05). 3.Compared with somatostatin group, the c-reactive protein levels of combination group at 4 h, 24 h, 48 h post ERCP were lower(P < 0.05).Conclusions:We find that indomethacin combined somatostatin treatment can obviously reduce the incidence of post-ERCP pancreatitis and the inflammation levels.